Review Papers Claim by Claim

 Quick Explanation Copied

 Long Explanation

Mechanistic Core of the Review

The authors' central model is a toxin-like interaction: pro-apoptotic Bax carries a conserved lysine (K128) that plugs the mitoKv1.3 pore, just as ShK toxin uses Lys22 to block the channel. Inhibition blocks inward K+ flux, hyperpolarizes the inner mitochondrial membrane, increases single-electron leakage at complexes I/III, elevates ROS, oxidizes the permeability transition pore, and releases cytochrome c K128 toxin-plug mechanism and reciprocal Bcl-xL mutant. The reciprocal mutation experiments (K128E Bax loses pro-apoptotic function; E158K Bcl-xL gains it) are the strongest causal support, supported by patch-clamp on mitoplasts, co-immunoprecipitation, and mitochondria-targeted Kv1.3 reconstitution that restored death in Kv1.3-deficient cells Mito-targeted Kv1.3 rescue experiment.

Note the pH dependence of Bax-mediated Kv1.3 inhibition (IC50 rising from 4 nM at neutral pH to 50 nM at pH 6.0) via protonation of His404; the review offers this as a mechanistic detail but leaves the physiological consequence underexplored pH-dependent Bax-Kv1.3 binding.

Therapeutic Evidence and Its Weaknesses

Clofazimine reduced orthotopic mouse melanoma burden by approximately 90%, and ex vivo B-CLL cells (which showed higher Kv1.3 expression than healthy B cells) were selectively killed by Psora-4, PAP-1, and clofazimine, while autologous T cells and healthy donor lymphocytes were largely spared Melanoma and B-CLL efficacy data. The authors attribute selective cancer killing to constitutively elevated oxidative stress in tumors pushing cells over an ROS threshold. This is plausible but inferential: no direct measurement linking baseline ROS to drug sensitivity was presented in this review, and the B-CLL/healthy-B-cell comparison is of limited value as the authors themselves concede.

Critical Limitations and Blind Spots

• Pharmacological specificity: Psora-4 and PAP-1 act on other Kv channels at higher concentrations, and clofazimine is a pleiotropic riminophenazine with antimycobacterial and anti-inflammatory actions; the review does not resolve whether cancer cell killing is mitoKv1.3-specific or partly off-target Drug specificity caveats. Subsequent work on mitochondria-targeted furocoumarin derivatives (e.g., PCTP) partially addressed this but remained in vitro Mitochondria-targeted furocoumarin follow-up.
• Molecular identity uncertainty: the field itself flags unresolved questions about the molecular identity and pharmacology of mitochondrial potassium channels; mitoKv1.3 lacks an obvious mitochondrial targeting sequence Field-wide uncertainty on mitoK channel identity.
• Concurrent channel biology: Bax also interacts with mitochondrial BK channels, raising redundancy or alternative mechanism questions the review acknowledges but does not test Bax-BK channel parallel mechanism.
• Small preclinical samples: the in vivo melanoma result derives from a single mouse model; no human cancer trial data existed at publication, and selectivity claims rest on limited ex vivo patient samples.

What would change this verdict: replication of tumor regression with Kv1.3 genetically invalid controls in vivo, structure-confirmed pore binding of the drugs to mitoKv1.3, or demonstration that normal tissue mitochondria tolerate chronic mitoKv1.3 inhibition.

Test the Bcl-2 Bypass HypothesisPredict Kv1.3 Drug Off-TargetsDesign Genetic Validation Experiments

Author Review: Luigi LeanzaAuthor Review: Elisa VenturiniAuthor Review: Stephanie KadowAuthor Review: Alexander CarpinteiroAuthor Review: Erich GulbinsAuthor Review: Anne Katrin Becker

 BGPT Paper Review

Study Novelty

Synthesizes an already-discovered mitoKv1.3-Bax axis into a novel therapeutic framing (bypassing Bcl-2 resistance) rather than a new discovery; conceptually fresh for 2014 but built on the group's own prior work.

Scientific Quality

A well-sourced review with strong mechanistic logic and reciprocal-mutation causal evidence, but authored largely by the discovering group (inherent confirmation risk), relying on potentially non-specific pharmacological tools and small preclinical samples.

Study Generality

Applies broadly to apoptosis biology across cancers, yet remains a niche mitochondrial channel pharmacology topic; mechanism is general but tested in few tumor types.

Study Usefulness

Provides a clear rationale for Kv1.3 inhibitor repurposing (clofazimine is an approved drug) and identifies explicit falsification-relevant targets, though no clinical validation existed at publication.

Study Reproducibility

Review-level reproducibility depends on the underlying primary experiments; methods are described, but no data deposits, and mitoplast patch-clamp plus off-target-prone drugs complicate independent replication.

Explanatory Depth

Deep mechanistic chain from K+ flux to hyperpolarization, ROS, PTP, and cytochrome c release, including residue-level toxin-plug logic and pH dependence.